helicobacter pylori eradication with a capsule containing.pdfVIP

Articles Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial Peter Malfertheiner, Franco Bazzoli, Jean-Charles Delchier, Krysztof Celiñski, Monique Giguère, Marc Rivière, Francis Mégraud, for the Pylera Study Group Summary Background Helicobacter pylori is associated with benign and malignant diseases of the upper gastrointestinal tract, Lancet 2011; 377: 905–13 and increasing antibiotic resistance has made alternative treatments necessary. Our aim was to assess the efficacy and Published Online safety of a new, single-capsule treatment versus the gold standard for H pylori eradication. February 22, 2011 DOI:10.1016/S0140- 6736(11)60020-2 Methods We did a randomised, open-label, non-inferiority, phase 3 trial in 39 sites in Europe, comparing the efficacy See Comment page 877 and safety of 10 days of quadruple therapy with omeprazole plus a single three-in-one capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline (quadruple therapy) versus 7 days of omeprazole, amoxicillin, Gastroenterologie, Hepatologie